Are you or someone you know still battling the fatigue, brain-fog or sleep troubles of Long COVID? A new trial published in The Lancet eClinicalMedicine (11/12/2025) tested high-dose nicotinamide riboside (NR) at 2,000 mg/day in adults with post-acute sequelae of SARS-CoV-2 infection — and the results are exciting. Here’s what we cover in the video: What the trial found: marked rises in NAD⁺ levels, and within-patient improvements in fatigue, sleep quality and mood. What the trial didn’t fully show: the between-group (NR vs placebo) difference did not reach full statistical significance — so this is promising, but not yet definitive. Why NAD⁺ matters — especially in aging cells, mitochondrial health and recovery from chronic illness. Practical take-homes for clinicians, senior-living professionals and integrative geriatrics teams: dosing, cost, context, safety. My clinician-insight: While this study highlights the potential of oral NR, I will continue to advocate for NAD⁺ injections in our practice — largely because of lower cost and much faster clinical benefit, particularly in the integrative geriatrics / long-COVID setting. Cost alert: For a high-quality branded oral NR product at 2,000 mg/day, you’re looking at hundreds of dollars per month — we’ll run through the numbers so you can decide if the value fits your setting. The actual product used in this study was made by Niagen: https://www.niagenplus.com/
Featured Experts
